Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Hagop M. Kantarjian, Elihu H. Estey, Susan O’Brien et al.|Cancer|2006Cited by 607
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia‐Manero, Jean‐Pierre J. Issa, Stefan Faderl et al.|Blood|2006Cited by 468
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|The Lancet Oncology|2012Cited by 411
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Emil J. Freireich, Farhad Ravandi et al.|Blood|2010Cited by 399
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|Cancer|2013Cited by 302